Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man.
The purpose of the present study of buprenorphine is to add information about the correlation between various animal models and nasal bioavailabilities in man. PEG 300 was added to one formulation to study whether the addition of the co-solvent results in the same absorption pattern as seen for sheep. The bioavailability of intranasal buprenorphine 0.6 mg in PEG 300 and 5% dextrose was assessed in a cross-over study in six rabbits. The mean bioavailabilities, Tmax and Cmax were 46% (S.D. +/-13) and 53% (S.D. +/-17), 8 and 12 min, 28 and 27 ng/ml for 30% PEG 300 and 5% dextrose, respectively. No significant differences were found between the nasal buprenorphine formulations. The bioavailabilities in rabbit and sheep, respectively, were approximately 2.5 and four times higher than for man. The absorption rate was faster for rabbit and sheep than for man. It appears that rabbit and sheep bioavailability differ from humans, especially with respect to rate. PEG 300 do not increase the bioavailability of buprenorphine.
Lindhardt
K
K
Department of Pharmaceutics, The Royal Danish School of Pharmacy, Universitetsparken 2, DK-2100 Ø, Copenhagen, Denmark.
Bagger
M
M
Andreasen
K H
KH
Bechgaard
E
E
D000281:Administration, Intranasal; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D001682:Biological Availability; D002047:Buprenorphine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005947:Glucose / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000378:metabolism*; D011817:Rabbits; D012756:Sheep; D012997:Solvents / Q000008:administration & dosage / Q000378:metabolism*; D013045:Species Specificity
D000701:Analgesics, Opioid; D012997:Solvents; D011092:Polyethylene Glycols; D002047:Buprenorphine; D005947:Glucose